Subscribe to RSS
DOI: 10.1055/s-0039-3402430
Genetic Background of von Willebrand Disease: History, Current State, and Future Perspectives
Funding Our work on VWD is supported by grants VEGA1/0187/17, VEGA 1/0168/16, and APVV 16–0020.Publication History
Publication Date:
30 December 2019 (online)
![](https://www.thieme-connect.de/media/sth/202004/lookinside/thumbnails/10-1055-s-0039-3402430_02711-1.jpg)
Abstract
Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 mutations and many disease-causing mechanisms have been described in the 35 years since the VWF gene was identified. Genetic testing in VWD patients is now available in many centers as a part of the VWD diagnostic algorithm. Molecular mechanisms leading to types 2 and 3 VWD are well characterized; thus, information from genetic analysis in these VWD types may be beneficial for their correct classification. However, the molecular basis of type 1 VWD is still not fully elucidated and most likely represents a multifactorial disorder reflecting a combined impact of environmental and genetic factors within and outside of VWF. Regarding sequencing methods, the previous gold-standard Sanger sequencing is gradually being replaced with next-generation sequencing methods that are more cost- and time-effective. Instead of gene-by-gene approaches, gene panels of genes for coagulation factors and related proteins have recently become a center of attention in patients with inherited bleeding disorders, especially because a high proportion of VWD patients, mainly those with low VWF plasma levels (type 1), appear to be free of mutations in VWF. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are accessible in a very limited number of laboratories. Results from these studies have presented several genes other than VWF or ABO possibly affecting VWF levels, and such findings will need further validation studies.
-
References
- 1 Von Willebrand EA. Hereditär pseudohemofili. Fin Lakaresallsk Handl 1926; 68: 87-112
- 2 Nilsson IM. The history of von Willebrand disease. Haemophilia 1999; 5 (Suppl. 02) 7-11
- 3 Ginsburg D, Handin RI, Bonthron DT. , et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228 (4706): 1401-1406
- 4 Lynch DC, Zimmerman TS, Collins CJ. , et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985; 41 (01) 49-56
- 5 Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985; 82 (19) 6394-6398
- 6 Verweij CL, de Vries CJ, Distel B. , et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13 (13) 4699-4717
- 7 Lynch DC, Zimmerman TS, Ruggeri ZM. von Willebrand factor, now cloned. Br J Haematol 1986; 64 (01) 15-20
- 8 Federici AB, Berntorp E, Lee CA. The 80th anniversary of von Willebrand's disease: history, management and research. Haemophilia 2006; 12 (06) 563-572
- 9 Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37 (05) 440-455
- 10 Stasko J, Sokol J, Dobrotova M. , et al. Von Willebrandova choroba – profylaxia a liečba. Vask med 2016; 8 (03) 116-121
- 11 Favaloro EJ. Preface to special issue: diagnosis and management of von Willebrand disease—diverse approaches to a global and common bleeding disorder. Ann Blood 2018; 3: 43
- 12 Favaloro EJ. Rare forms of von Willebrand disease. Ann Transl Med 2018; 6 (17) 345
- 13 Kubisz P, Sokol J, Simurda T. , et al. Diagnosis and management of von Willebrand disease in Slovakia. Ann Blood 2018; 3: 9
- 14 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21 (03) 178-183
- 15 de Jong A, Eikenboom J. Von Willebrand disease mutation spectrum and associated mutation mechanisms. Thromb Res 2017; 159: 65-75
- 16 Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25 (03) 206-216
- 17 Sadler JE, Budde U, Eikenboom JC. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
- 18 James PD, Goodeve AC. von Willebrand disease. Genet Med 2011; 13 (05) 365-376
- 19 Marder VJ, Aird WC, Bennett JS, Schulman S, White II GC. Hemostasis and Thrombosis: Basic principles and Clinical Practice. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013: 197-207 , 670–683
- 20 Baronciani L, Goodeve A, Peyvandi F. Molecular diagnosis of von Willebrand disease. Haemophilia 2017; 23 (02) 188-197
- 21 Mancuso DJ, Tuley EA, Westfield LA. , et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30 (01) 253-269
- 22 Ginsburg D, Bowie EJW. Molecular genetics of von Willebrand disease. Blood 1992; 79 (10) 2507-2519
- 23 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (03) 123-134
- 24 Gupta PK, Adamtziki E, Budde U. , et al. Gene conversions are a common cause of von Willebrand disease. Br J Haematol 2005; 130 (05) 752-758
- 25 Ahmad F, Kannan M, Obser T. , et al. Characterization of VWF gene conversions causing von Willebrand disease. Br J Haematol 2019; 184 (05) 817-825
- 26 Tutar Y. Pseudogenes. Comp Funct Genomics 2012; 2012: 424526
- 27 Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010; 8 (01) 6-12
- 28 Campos M, Sun W, Yu F. , et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117 (19) 5224-5230
- 29 Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost 2013; 11 (02) 261-269
- 30 Hickson N, Hampshire D, Castaman G. , et al; MCMDM-1VWD and ZPMCB-VWD Study Groups. Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions. J Thromb Haemost 2011; 9 (03) 603-605
- 31 Goodeve A. Diagnosing von Willebrand disease: genetic analysis. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 678-682
- 32 Flood VH. New insights into genotype and phenotype of VWD. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (01) 531-535
- 33 James PD, Notley C, Hegadorn C. , et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109 (01) 145-154
- 34 Castaman G, Eikenboom JCJ. ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854GIn, and the missense mutation Cys2362Phe. Blood 2002; 100 (05) 1927-1928
- 35 Berber E. The molecular genetics of von Willebrand disease. Turk J Haematol 2012; 29 (04) 313-324
- 36 Cumming A, Grundy P, Keeney S. , et al; UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96 (05) 630-641
- 37 Goodeve A, Eikenboom J, Castaman G. , et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109 (01) 112-121
- 38 Favaloro EJ. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost 2008; 6 (11) 1999-2001 , author reply 2002–2003
- 39 James PD, Lillicrap D. The molecular characterization of von Willebrand disease: good in parts. Br J Haematol 2013; 161 (02) 166-176
- 40 Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. ; UK Haemophilia Centre Doctors' Organisation (UKHCDO). The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia 2008; 14 (05) 1099-1111
- 41 Shen MC, Chen M, Ma GC. , et al. De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD. Thromb J 2016; 14 (Suppl. 01) 36
- 42 Freitas SDS, Rezende SM, de Oliveira LC. , et al. Genetic variants of VWF gene in type 2 von Willebrand disease. Haemophilia 2019; 25 (02) e78-e85
- 43 König G, Obser T, Marggraf O. , et al. Alteration in GPIIb/IIIa binding of VWD-associated von Willebrand factor variants with C-terminal missense mutations. Thromb Haemost 2019; 119 (07) 1102-1111
- 44 Pruthi RK. A practical approach to genetic testing for von Willebrand disease. Mayo Clin Proc 2006; 81 (05) 679-691
- 45 Hassenpflug WA, Budde U, Obser T. , et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006; 107 (06) 2339-2345
- 46 O'Brien LA, Sutherland JJ, Weaver DF, Lillicrap D. Theoretical structural explanation for group I and group II, type 2A von Willebrand disease mutations. J Thromb Haemost 2005; 3 (04) 796-797
- 47 Lynch CJ, Cawte AD, Millar CM, Rueda D, Lane DA. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct. PLoS One 2017; 12 (11) e0188405
- 48 Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Mannucci PM. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost 2005; 3 (12) 2689-2694
- 49 Casonato A, Daidone V, Galletta E, Bertomoro A. Type 2B von Willebrand disease with or without HMW multimers: a distinction of two sides of the disorder is long overdue. PLoS One 2017; 12 (06) e0179566
- 50 Swystun LL, James PD. Genetic diagnosis in hemophilia and von Willebrand disease. Blood Rev 2017; 31 (01) 47-56
- 51 Favaloro EJ, Bonar RA, Mohammed S. , et al. Type 2M von Willebrand disease - more often misidentified than correctly identified. Haemophilia 2016; 22 (03) e145-e155
- 52 Flood VH, Schlauderaff AC, Haberichter SL. , et al; Zimmerman Program Investigators. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood 2015; 125 (14) 2297-2304
- 53 Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia 2013; 19 (04) 590-594
- 54 Flood VH, Lederman CA, Wren JS. , et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010; 8 (06) 1431-1433
- 55 Riddell AF, Gomez K, Millar CM. , et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114 (16) 3489-3496
- 56 Ribba AS, Loisel I, Lavergne JM. , et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86 (03) 848-854
- 57 Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: similar but different. Semin Thromb Hemost 2016; 42 (05) 483-497
- 58 Casonato A, Galletta E, Sarolo L, Daidone V. Type 2N von Willebrand disease: characterization and diagnostic difficulties. Haemophilia 2018; 24 (01) 134-140
- 59 Shiltagh N, Kirkpatrick J, Cabrita LD. , et al. Solution structure of the major factor VIII binding region on von Willebrand factor. Blood 2014; 123 (26) 4143-4151
- 60 Przeradzka MA, Meems H, van der Zwaan C. , et al. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding. Biochem J 2018; 475 (17) 2819-2830
- 61 Bowman M, Tuttle A, Notley C. , et al; Association of Hemophilia Clinic Directors of Canada. The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles. J Thromb Haemost 2013; 11 (03) 512-520
- 62 Baronciani L, Cozzi G, Canciani MT. , et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30 (03) 264-270
- 63 James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood 2013; 122 (05) 636-640
- 64 Federici AB, James P. Current management of patients with severe von Willebrand disease type 3: a 2012 update. Acta Haematol 2012; 128 (02) 88-99
- 65 Elayaperumal S, Fouzia NA, Biswas A. , et al. Type-3 von Willebrand disease in India-clinical spectrum and molecular profile. Haemophilia 2018; 24 (06) 930-940
- 66 Vangenechten I, Smejkal P, Zapletal O. , et al. Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): results from the BRNO-VWD Study. Thromb Haemost 2019; 119 (04) 594-605
- 67 Batlle J, Pérez-Rodríguez A, Corrales I. , et al; PCM-EVW-ES Investigators Team. Update on molecular testing in von Willebrand disease. Semin Thromb Hemost 2019; 45 (07) 708-719
- 68 Corrales I, Ramírez L, Altisent C, Parra R, Vidal F. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009; 101 (03) 570-576
- 69 Peake IR, Goodeve AC. Genetic testing for von Willebrand disease: the case for. J Thromb Haemost 2010; 8 (01) 13-16
- 70 Rao ES, Ng CJ. Current approaches to diagnostic testing in von Willebrand disease. Transfus Apheresis Sci 2018; 57 (04) 463-465
- 71 Cumming AM, Keeney S, Jenkins PV, Nash MJ, O'Donnell JS. Clinical utility gene card for: von Willebrand disease. Eur J Hum Genet 2011 19(05):
- 72 Atiq F, Fijnvandraat K, van Galen KPM. , et al. BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. Am J Hematol 2019; 94 (08) E201-E205
- 73 Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost 2018; 16 (12) 2375-2390
- 74 Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019; 45 (07) 661-673
- 75 Cabrera N, Casaña P, Cid AR. , et al. First application of MLPA method in severe von Willebrand disease. Confirmation of a new large VWF gene deletion and identification of heterozygous carriers. Br J Haematol 2011; 152 (02) 240-242
- 76 Bastida JM, González-Porras JR, Jiménez C. , et al. Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. Thromb Haemost 2017; 117 (01) 66-74
- 77 Bastida JM, Del Rey M, Lozano ML. , et al. Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders. Haemophilia 2016; 22 (04) 590-597
- 78 Saes JL, Simons A, de Munnik SA. , et al. Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis. Haemophilia 2019; 25 (01) 127-135
- 79 Pezeshkpoor B, Zimmer N, Marquardt N. , et al. Deep intronic 'mutations' cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA. J Thromb Haemost 2013; 11 (09) 1679-1687
- 80 Smith NL, Chen MH, Dehghan A. , et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
- 81 Sabater-Lleal M, Huffman JE, de Vries PS. , et al; INVENT Consortium; MEGASTROKE Consortium of the International Stroke Genetics Consortium (ISGC). Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von Willebrand factor plasma levels. Circulation 2019; 139 (05) 620-635
- 82 Ward S, O'Sullivan JM, O'Donnell JS. von Willebrand factor sialylation-a critical regulator of biological function. J Thromb Haemost 2019; 17 (07) 1018-1029
- 83 Xiang Y, Cheng J, Wang D. , et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015; 125 (22) 3377-3387
- 84 Xiang Y, Hwa J. Regulation of VWF expression, and secretion in health and disease. Curr Opin Hematol 2016; 23 (03) 288-293